RNAC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RNAC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cartesian Therapeutics's total current liabilities for the quarter that ended in Dec. 2024 was $22.98
The historical data trend for Cartesian Therapeutics's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cartesian Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Total Current Liabilities | Get a 7-Day Free Trial |
![]() |
![]() |
81.55 | 72.25 | 25.08 | 68.21 | 22.98 |
Cartesian Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Total Current Liabilities | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
68.21 | 36.65 | 26.12 | 21.41 | 22.98 |
Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.
Cartesian Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 12.364 | + | 2.851 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 7.761 | + | 0 | |
= | 22.98 |
Cartesian Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 12.364 | + | 2.851 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 7.761 | + | 0 | |
= | 22.98 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Be Aware
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of Cartesian Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Timothy A Springer | director | 36 WOODMAN ROAD, CHESTNUT HILL MA 02467 |
Blaine Davis | officer: Chief Financial Officer | C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014 |
Carsten Brunn | director, officer: President & CEO | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Timothy C Barabe | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Peter G Traber | officer: Chief Medical Officer | 430 THAMER LANE, HOUSTON TX 77025 |
Takashi Kei Kishimoto | officer: Chief Scientific Officer | 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472 |
Lloyd P. Johnston | officer: COO and SVP, R&D | 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472 |
Carrie Smith Cox | director | SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Kevin Tan | officer: Chief Financial Officer | 20 HICKORY ROAD, WELLESLEY MA 02482 |
Nishan M Desilva | director | 11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037 |
Ann K. Donohue | officer: VP Finance | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472 |
Bradford D. Dahms | officer: Chief Financial Officer | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Goran Ando | director | |
Scott Dunseth Myers | director | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Elona Esq. Kogan | officer: General Counsel | C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065 |
From GuruFocus
By Marketwired • 09-09-2024
By Marketwired • 01-07-2025
By Marketwired • 11-21-2024
By Marketwired • 08-26-2024
By Marketwired • 02-06-2025
By Marketwired • 07-02-2024
By Marketwired • 08-07-2024
By Marketwired • 02-18-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.